Neurodegenerative Diseases
155
36
45
63
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
12 trials with published results (8%)
Research Maturity
63 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.2%
5 terminated out of 155 trials
92.6%
+6.1% vs benchmark
5%
7 trials in Phase 3/4
19%
12 of 63 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 63 completed trials
Clinical Trials (155)
Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS)
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Impact of Harp Therapy on Behavioral Disorders in Nursing Home Residents With Neurodegenerative Disease (ARPE)
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Neurologic Stem Cell Treatment Study
Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
AMX0035 and Progressive Supranuclear Palsy
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Novel Technologies to Measure Vision-related Quality of Life
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases
NAD+ Oral Supplement Pilot Intervention in Adult Females